» Articles » PMID: 22654868

Craniopharyngioma in Adults

Overview
Specialty Endocrinology
Date 2012 Jun 2
PMID 22654868
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Craniopharyngiomas are slow growing benign tumors of the sellar and parasellar region with an overall incidence rate of approximately 1.3 per million. During adulthood there is a peak incidence between 40 and 44 years. There are two histopathological types, the adamantinomatous and the papillary type. The later type occurs almost exclusively in adult patients. The presenting symptoms develop over years and display a wide spectrum comprising visual, endocrine, hypothalamic, neurological, and neuropsychological manifestations. Currently, the main treatment option consists in surgical excision followed by radiation therapy in case of residual tumor. Whether gross total or partial resection should be preferred has to be balanced on an individual basis considering the extent of the tumor (e.g., hypothalamic invasion). Although the overall long-term survival is good it is often associated with substantial morbidity. Preexisting disorders are often permanent or even exacerbated by treatment. Endocrine disturbances need careful replacement and metabolic sequelae should be effectively treated. Regular follow-up by a multidisciplinary team is a prerequisite for optimal outcome of these patients.

Citing Articles

The clinical significance of inflammatory mediators in predicting obesity and progression-free survival in patients with adult-onset Craniopharyngioma.

Xiao Y, Wu W, Liu F, Jia Y, Jin L, Qiao N BMC Cancer. 2024; 24(1):799.

PMID: 38965454 PMC: 11229012. DOI: 10.1186/s12885-024-12548-4.


Craniopharyngioma: A comprehensive review of the clinical presentation, radiological findings, management, and future Perspective.

Alboqami M, Khalid S Albaiahy A, Bukhari B, Alkhaibary A, Alharbi A, Khairy S Heliyon. 2024; 10(11):e32112.

PMID: 38961911 PMC: 11219339. DOI: 10.1016/j.heliyon.2024.e32112.


A 55-Year-Old Woman Presenting with a Second Diagnosis of Craniopharyngioma Following Diagnosis and Successful Treatment of Craniopharyngioma as a 5-Year-Old Child.

Alarayedh A, Sulimani R, Alsaeed E, Alkhalidi H, Ajlan A, Abdu A Am J Case Rep. 2024; 25:e943300.

PMID: 38857198 PMC: 11180480. DOI: 10.12659/AJCR.943300.


Presentation and outcomes of paediatric craniopharyngioma in the west of Scotland: a 25 year experience.

Kuah X, Lucas-Herald A, McCarrison S, Boyle R, Adey C, Amato-Watkins A J Neurooncol. 2024; 166(1):51-57.

PMID: 38224403 DOI: 10.1007/s11060-023-04490-5.


Epidemiology of craniopharyngiomas: a population-based study in Malta.

Craus S, Gruppetta M Endocr Oncol. 2023; 1(1):9-16.

PMID: 37435184 PMC: 10265539. DOI: 10.1530/EO-21-0006.


References
1.
Crotty T, Scheithauer B, Young Jr W, Davis D, Shaw E, Miller G . Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg. 1995; 83(2):206-14. DOI: 10.3171/jns.1995.83.2.0206. View

2.
Campanini M, Colli L, Paixao B, Cabral T, Amaral F, Machado H . CTNNB1 gene mutations, pituitary transcription factors, and MicroRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas. Horm Cancer. 2011; 1(4):187-96. PMC: 10358030. DOI: 10.1007/s12672-010-0041-7. View

3.
Voges J, Sturm V, Lehrke R, Treuer H, Gauss C, Berthold F . Cystic craniopharyngioma: long-term results after intracavitary irradiation with stereotactically applied colloidal beta-emitting radioactive sources. Neurosurgery. 1997; 40(2):263-9; discussion 269-70. DOI: 10.1097/00006123-199702000-00006. View

4.
Rutka J . Craniopharyngioma. J Neurosurg. 2002; 97(1):1-2; discussion 2. DOI: 10.3171/jns.2002.97.1.0001. View

5.
Garre M, Cama A . Craniopharyngioma: modern concepts in pathogenesis and treatment. Curr Opin Pediatr. 2007; 19(4):471-9. DOI: 10.1097/MOP.0b013e3282495a22. View